Entity
Description
  • Value proposition

    AI for digital twin of cells

    DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.

    While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.

    The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.

    We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.


    Drug Discovery, Pharmaceutical, Deep Learning, and Biotech

  • Original language

    AI for digital twin of cells

    DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells.

    While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases.

    The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.

    We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.

  • DeepLife | Digital Twin of Cells for Drug Discovery

    At DeepLife, we harness deep learning on multi-omics data to model cells and efficiently engineer their behavior

  • https://www.deeplife.co/
Corporate interactions
Corporate TypeTweets Articles
UCB
UCB
Pharmaceutical Manufacturing
UCB
Pharmaceutical Manufacturing
Other

11 Mar 2025


Capgemini
Capgemini
Consulting, IT Services and IT Consulting
Capgemini
Consulting, IT Services and IT Consulting
Other

11 Mar 2025


numeum
numeum
IT Services and IT Consulting
numeum
IT Services and IT Consulting
Other

13 Feb 2025


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking
Other

13 Feb 2025


Future4Care
Future4Care
Startup accelerator & VC
Future4Care
Startup accelerator & VC
Other

17 Mar 2025


Rise Partners Rise Partners
Other

16 Dec 2024


Sifted
Sifted
Newspaper Publishing
Sifted
Newspaper Publishing
Other

11 Dec 2024


Beiersdorf
Beiersdorf
Cosmetics, Chemistry, Personal Care Product Manufacturing
Beiersdorf
Cosmetics, Chemistry, Personal Care Product Manufacturing
Other

11 Dec 2024


Entrepreneur First
Entrepreneur First
Startup accelerator & VC, Venture Capital and Private Equity Principals
Entrepreneur First
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

18 Dec 2024


STATION F
STATION F
Startup accelerator & VC, Software Development
STATION F
Startup accelerator & VC, Software Development
Other

13 Feb 2025


Similar entities
Loading...
Loading...
Social network dynamics